Response to the letter of Hoermann and colleagues

Robin P. Peeters*, Juan P. Brito

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorProfessional


We read the letter by Hoermann and colleagues with great interest and are thankful for the opportunity to discuss some of their remarks.
The authors raise the issue that part of the controversy regarding the treatment of subclinical hypothyroidism (SCH) is related to how we define SCH and whether it is a true disease or merely a laboratory constellation.
Although we wrote a debate on whether SCH should be treated or not, we generally agree that the biochemical diagnosis of SCH covers a wide spectrum of patients. We, therefore, agree that SCH can be a true disease in one patient but a laboratory constellation in another. Based on the progression rate to overt hypothyroidism, the extent of TSH elevation is a good discriminator between the two. Consequently, we have a consensus on the treatment of SCH in the vast majority of cases. For example, in the case of a very mildly elevated TSH, and FT4 above the median and negative TPO-antibodies (case A), we both agreed not to start with levothyroxine (LT4) therapy, whereas in the case of a clearly elevated TSH, positive TPO-antibodies and a low-normal FT4 (case B) we both agreed to start with LT4 therapy. However, as always in medicine, there is a grey zone, such as when SCH is diagnosed based on a TSH between 7 and 10 mIU/L and nonspecific symptoms. Unfortunately, adequately powered clinical trials with patients in this grey zone are lacking. For these patients, we fully agree with Hoermann and colleagues that the measurement of only a TSH cannot reliably discriminate between true disease or laboratory variation. This uncertainty about SCH diagnosis and its association with patient symptomatology has confused patients and clinicians in how to best address it. Hoermann and colleagues proposed a strategy that relies more on clinical manifestations (e.g. symptoms of hypothyroidism) and less on TSH values. The fact the hypothyroidism symptoms are nonspecific (5) suggests that this approach will not be able to provide a clear-cut answer either. Alternatively, we see this grey zone as an opportunity to bring the uncertainty about SCH diagnosis and treatment in the conversation with the patient to find the best strategy that responds to the situation. Sometimes the clinician’s response demands focusing on addressing symptoms (e.g. investigate other etiologies of fatigue) as opposed to lowering TSH values. At other times, the clinician’s response could be a therapeutic trial with the LT4 to normalize TSH and patient re-assessment for symptom change or resolution. Future research will provide more clarity about the diagnosis of SCH and the effectiveness of treatment. In the meantime, we should welcome the uncertainty of SCH diagnosis and treatment as an opportunity to work together with our patients and uncover what is best for them.
Original languageEnglish
Pages (from-to)L7-L8
JournalEuropean Journal of Endocrinology
Issue number3
Publication statusPublished - Sep 2021


Dive into the research topics of 'Response to the letter of Hoermann and colleagues'. Together they form a unique fingerprint.

Cite this